Quipt Home Medical Corp

Quipt Home Medical Corp. (NASDAQ: QIPT) is a home medical equipment provider. The Company provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units, traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services.

Recent Business and Financial Updates

• Revenue Growth and Financial Performance: Quipt achieved a revenue of USD 245.9 million in fiscal year 2024, representing a 16.2% increase compared to USD 211.7 million in fiscal year 2023. Organic growth accounted for approximately USD 7.1 million or 3% of this increase. The transition from IFRS to U.S. GAAP resulted in a USD 10.1 million revenue adjustment for fiscal year 2023, with no impact on Adjusted EBITDA or net loss. Fiscal year 2024 revenues were adversely affected by the suspension of the Medicare 75/25 relief program and the withdrawal of Medicare Advantage members, which reduced revenue by approximately USD 5 million. Additionally, a cyberattack in February 2024 impacted cash collections of accounts receivable, estimated at USD 3 million.
• Recurring Revenue and EBITDA Trends: Recurring Revenue remained a cornerstone of the company’s financial performance, constituting approximately 78% of total revenue, driven by the expansion of Quipt’s resupply platform. Adjusted EBITDA for fiscal year 2024 rose by 14.3% to USD 57.9 million, achieving a margin of 23.5%. This performance reflects an improvement from the USD 50.6 million Adjusted EBITDA and 23.9% margin in fiscal year 2023. Net loss for fiscal year 2024 stood at USD 6.8 million, or (USD 0.16) per diluted share, compared to USD 2.8 million, or (USD 0.07) per diluted share, in the prior year.
• Quarterly Highlights and Sequential Growth: In Q4 2024, Quipt generated USD 61.3 million in revenue, marking a 3% year-over-year increase from USD 59.6 million in Q4 2023. Sequential organic revenue growth was approximately 1%. Adjusted EBITDA for Q4 2024 was USD 13.4 million, reflecting a margin of 21.8%, compared to USD 14.7 million and a 24.6% margin in Q4 2023. This represents an 8.8% year-over-year decline, underscoring the challenges faced during the fiscal year.
• Operational Achievements and Customer Expansion: The company continued to expand its customer base, reaching approximately 153,000 unique patients in Q4 2024, a 4% increase from 147,000 in Q4 2023. Fiscal year 2024 saw 854,000 unique set-ups and deliveries, a 13% rise from 754,000 in the previous year. Respiratory resupply set-ups accounted for 480,000 of these, marking a 21% increase from the prior year. The company’s resupply program now serves 172,000 patients and represents 51% of the Recurring Revenue mix. Demand and referral activity remained consistent across all major product categories, supported by a network of 36,000 referring physicians and 135 operational locations.
• Cash Flow and Liquidity Position: Cash flow from operations totaled USD 35.4 million in fiscal year 2024, compared to USD 37 million in fiscal year 2023. The company reported USD 16.2 million in cash on hand as of September 30, 2024, up from USD 14.4 million as of June 30, 2024. Quipt’s total credit availability stood at USD 34.7 million, comprising USD 13.7 million under a revolving credit facility and USD 21 million through a delayed-draw term loan facility. The company maintained a conservative financial profile with a Net Debt to Adjusted EBITDA Leverage Ratio of 1.6x.
• Strategic Vision and Future Outlook:
  • Gregory Crawford, Chairman and CEO, highlighted the resilience of Quipt’s business model and its adaptability amid fiscal challenges. The company remains committed to leveraging demographic trends, such as the aging population and the increasing prevalence of chronic respiratory conditions, to sustain long-term growth. Efforts to expand the referral base, strengthen the salesforce, and pursue disciplined inorganic growth are expected to enhance market position.
  • Hardik Mehta, Chief Financial Officer, expressed confidence in the company’s ability to achieve consistent organic growth in 2025, supported by strong demand for in-home respiratory solutions and favorable demographic trends. With a scalable operating model and strategic focus, Quipt is well-positioned to capitalize on growth opportunities while delivering sustained shareholder value.
    

Technical Observation (on the daily chart):

The Relative Strength Index (RSI) over a 14-day period stands at a value of 58.70, currently recovered from overbought zone, with expectations of a consolidation or an upward momentum if the current resistance of USD 3.00- USD3.30 is broken on the upside. Additionally, the stock's current positioning is between both the 50-period SMA and 200-period SMA, which may serve as dynamic short to medium-term support and resistance levels respectively.  

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given for Quipt Home Medical Corp. (NASDAQ: QIPT) at the current market price of USD 2.93, as of January 02, 2025, at 10:15 am PST. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is January 02, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.